PMID- 29285385
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 7
IP  - 6
DP  - 2017 Dec
TI  - MHC class II associated stomach cancer mutations correlate with lack of 
      subsequent tumor development.
PG  - 1119-1121
LID - 10.3892/mco.2017.1432 [doi]
AB  - The role of tumor cell expression of major histocompatibility class II (MHCII) 
      has been controversial, with evidence indicating that tumor cell expression of 
      MHCII may lead to an anti-tumor immune response and to tumor cell apoptosis and 
      that MHCII has pro-tumorigenic functions. The cancer genome atlas (TCGA) 
      indicates numerous deleterious mutations for the highly specific, MHCII 
      transcriptional activation proteins, RFX5, RFXAP, RFXANK and CIITA. Also, 
      mutations in the non-polymorphic, human leukocyte antigen (HLA)-DRA gene, which 
      encodes the heavy chain for the most prominent human MHCII molecule, HLA-DR, are 
      common. For many, if not most TCGA cancer datasets, the MHCII specific mutations 
      do not associate with clinical outcomes. However, stomach carcinoma represents an 
      exception, where the data indicate that MHCII-specific mutations are associated 
      with a more favorable outcome. These data raise the question of whether stomach 
      cancer mutations represent effective haploinsufficiency or whether mutations that 
      are associated with a favorable outcome occur with other stomach cancer molecular 
      features that limit the function of the two alleles that represent these 
      MHCII-related proteins.
FAU - Yavorski, John M
AU  - Yavorski JM
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, Tampa, FL 33612, USA.
FAU - Blanck, George
AU  - Blanck G
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, Tampa, FL 33612, USA.
AD  - Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, 
      FL 33612, USA.
LA  - eng
PT  - Journal Article
DEP - 20170929
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC5740846
OTO - NOTNLM
OT  - HLA-DR
OT  - interferon-gamma induction
OT  - major histocompatibility class II proteins
OT  - prognosis
OT  - solid tumor
OT  - stomach cancer
EDAT- 2017/12/30 06:00
MHDA- 2017/12/30 06:01
PMCR- 2017/09/29
CRDT- 2017/12/30 06:00
PHST- 2017/02/09 00:00 [received]
PHST- 2017/08/17 00:00 [accepted]
PHST- 2017/12/30 06:00 [entrez]
PHST- 2017/12/30 06:00 [pubmed]
PHST- 2017/12/30 06:01 [medline]
PHST- 2017/09/29 00:00 [pmc-release]
AID - MCO-0-0-1432 [pii]
AID - 10.3892/mco.2017.1432 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2017 Dec;7(6):1119-1121. doi: 10.3892/mco.2017.1432. Epub 2017 
      Sep 29.